CareDx’s AlloCare App Now Integrated with TxAccess to Help Pre-Transplant Patients Navigate the Waitlist Process

New Attributes Goal to Enable Much more Clients with Kidney Failure Obtain an Organ Transplant

CareDx AlloCare transplant app

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (Globe NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ concentrated on the discovery, progress, and commercialization of clinically differentiated, high-worth health care alternatives for transplant individuals and caregivers – currently introduced that its well-liked, consumer-pleasant AlloCare® mobile phone overall health application, now functions a “virtual roadmap” to support patients track and finish the specifications desired to be regarded as for placement on a transplant waiting around list.

There are around 550,000 patients on dialysis in the United States, numerous of whom might be eligible for a transplant.¹ Of these patients on dialysis, only 13.5 % are on a ready record.¹ The patient’s journey from receiving a transplant referral to remaining put on a waiting checklist is complex. Individuals have to go through rigorous screening that frequently spans months and contains many appointments, like diagnostic exams, dietary assessments, psycho-social evaluations, and financial eligibility. This complicated array of responsibilities is often tricky for the patient to keep track of and regulate.

“The AlloCare application can now be used by both pre- and write-up-transplant people. This new improvement empowers pre-transplant sufferers to consider management of the waitlisting approach,” mentioned Reg Seeto, CEO and President of CareDx. “Now that the TxAccess™ communication instrument is absolutely integrated, AlloCare consumers can very easily link with their referring company and transplant heart in controlling this advanced journey.”

“As a kidney transplant recipient, I know first-hand how frustrating the transplant waiting around list approach can be. There are several checks necessary, and just one misstep in fulfilling a phase can necessarily mean the distinction involving getting on a waitlist or not,” stated Patrick Gee Sr., Ph.D., a kidney recipient, and transplant client advocate. “As a longtime user of the AlloCare application, I am thrilled to hear the news that this pre-transplant ‘virtual roadmap’ aspect is now provided to empower far more patients in efficiently taking care of the sophisticated kidney transplant method from referral, to receiving on a waitlist, to finally receiving their substantially-desired kidney transplant.”

Story proceeds

Because its introduction in September 2020, the AlloCare cell app has been downloaded much more than 25,000 moments.² AlloCare previously assists sufferers navigate their write-up-transplant journey by giving resources to observe their own health and fitness metrics and examination outcomes, take care of their elaborate medicine regimens, and join with other people who have experienced a transplant. Now, these new enhancements powerfully url participating transplant facilities, referring providers, and pre-transplant clients in better navigating the intricate pre-transplant process so that far more sufferers finally receive a transplant.

About CareDx – The Transplant Firm
CareDx, Inc., headquartered in South San Francisco, California, is a main precision medicine solutions enterprise targeted on the discovery, advancement, and commercialization of clinically differentiated, high-price healthcare answers for transplant clients and caregivers. CareDx offers testing expert services, merchandise, and digital healthcare solutions alongside the pre- and write-up-transplant affected person journey and is the primary company of genomics-based facts for transplant clients. For far more information, you should stop by: www.CareDx.com.

Ahead-Wanting Statements
This push launch incorporates forward-wanting statements linked to CareDx, Inc., including statements with regards to the likely gains and benefits that could be accomplished with the new digital roadmap attribute on CareDx’s AlloCare cell overall health app by integrating TxAccess platform (the “New Feature”). These forward-on the lookout statements are based mostly upon details that is at the moment accessible to CareDx and its present-day expectations, speak only as of the day hereof, and are matter to risks and uncertainties that could result in actual outcomes to differ materially from people projected, together with pitfalls that CareDx does not understand the envisioned gains of the New Aspect general financial and marketplace aspects and other challenges talked about in CareDx’s filings with the SEC, together with the Once-a-year Report on Sort 10-K for the fiscal yr finished December 31, 2021, filed by CareDx with the SEC on February 24, 2022, and other experiences that CareDx has filed with the SEC. Any of these may perhaps lead to CareDx’s actual benefits, efficiency, or achievements to vary materially and adversely from those people predicted or implied by CareDx’s forward-seeking statements. CareDx expressly disclaims any obligation, apart from as necessary by law, or endeavor to update or revise any this sort of forward-looking statements.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Promoting Officer
415-287-2393
[email protected]

Trader Relations
Ian Cooney
(415) 722-4563
[email protected]

References:

1. United States Renal Information Procedure 2020 Annual Knowledge Report. https://adr.usrds.org/2020/finish-stage-renal-ailment. Accessed online March 1, 2022.

2. CareDx facts on file. March 21, 2022.